Clinical Trials on Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma in Canada

Total 279 results

University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma

United States, Canada, Australia, New Zealand, Puerto Rico, Israel
Aegera Therapeutics
The Leukemia and Lymphoma Society

Terminated

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

Canada, United States
Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditions

United States, Canada
British Columbia Cancer Agency

Not yet recruiting

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Multiple Myeloma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma

Canada
AbbVie

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Israel
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Celgene

Active, not recruiting

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma, Non-Hodgkin

Canada, Spain, United States, Austria
Eleah Stringer
BC Cancer Foundation

Completed

Intermittent Fasting and CLL/SLL

Neoplasms | Inflammation | Lymphoma, Small Lymphocytic | Diet Habit | Intermittent Fasting | Leukemia, Lymphocytic, Chronic

Canada
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Peripheral T-cell Lymphoma | Lymphoid Malignancies | Chronic Lymphoid Leukemia

United States, Canada
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
Lundbeck Canada Inc.

Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BENDACT)

Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

Canada
Prelude Therapeutics
BeiGene

Recruiting

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies

T-cell Lymphoma | Mantle Cell Lymphoma (MCL) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Syndrome | Aggressive B-Cell Non-Hodgkin's Lymphoma | Aggressive B-Cell NHL

United States, Canada, Korea, Republic of, Australia, France, Poland, Italy, Germany, Switzerland, United Kingdom
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
Sunnybrook Health Sciences Centre
Merck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL)

Recurrent | Adult Diffuse Large Cell Lymphoma | Adult Refractory Diffuse Large B-Cell Lymphoma

Canada
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR)

Recruiting

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada
BeiGene

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States, Spain, Italy, Australia, France, Korea, Republic of, Canada, Georgia, Sweden, Germany, Moldova, Republic of
Kite, A Gilead Company

Recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Canada, Belgium, Poland, Czechia, Italy, France, Germany, Netherlands, Sweden
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Lymphoma | Leukemia

Canada
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
British Columbia Cancer Agency
University of Victoria; BC Cancer Foundation

Completed

A Case Crossover Study of Intermittent Fasting in CLL/SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Canada
The Hospital for Sick Children

Terminated

Yoga Fatigue Study

Acute Myeloid Leukemia (AML) | Acute Lymphocytic Leukemia in Relapse | Burkitt's Lymphoma Stage III | Burkitt's Lymphoma Stage IV | Type 3 Diffuse Large B-Cell Lymphoma

Canada, United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Kite, A Gilead Company

Recruiting

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Relapsed/Refractory Large B-cell Lymphoma

United States, Australia, Canada
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Chronic Lymphocytic Leukemia | Leukemia, B-cell | Small Lymphocytic Lymphoma | Leukemia, Lymphocytic

United States, Spain, Canada, Korea, Republic of, Taiwan, Australia, Japan, New Zealand, Italy, Czechia, China, Hungary, Israel, Belgium, France, Poland, Germany, Argentina, United Kingdom, Brazil, Turkey, Chile, Austria
Astellas Pharma Inc

Terminated

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Lymphoma, Large-Cell, Diffuse | Lymphoma, B-Cell Refractory

France, Spain, United States, Canada
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States, Canada, Israel, Australia, Puerto Rico
SecuraBio

Terminated

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Lymphoma, Small Lymphocytic | Lymphocytic Leukemia, Chronic

United States, Canada
University Health Network, Toronto
Novartis

Completed

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

Canada
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

Australia, Spain, United States, France, Hungary, New Zealand, Poland, Serbia, Canada, Romania
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel, Taiwan, United Kingdom, Chile, Canada, Japan, Brazil
GWT-TUD GmbH
Hoffmann-La Roche

Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-cell Lymphoma

Germany, Spain, United Kingdom, Austria
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
Kite, A Gilead Company

Active, not recruiting

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
Celgene

Completed

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Relapsed or Refractory Chronic Lymphocytic Leukemia

United States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States, China, Poland, Israel, Canada, Chile, Czechia, Estonia, France, Greece, Italy, Korea, Republic of, Norway, Spain, Sweden, Thailand, Turkey
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
AstraZeneca
Parexel

Active, not recruiting

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

United States, Korea, Republic of, Canada, United Kingdom, Spain, France, Denmark
University Health Network, Toronto

Not yet recruiting

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (GRAIL)

Diffuse Large B Cell Lymphoma (DLBCL)

Canada
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditions

United States, Canada, Australia, Puerto Rico
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States

Clinical Trials on Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations